Food allergy is increasing globally and has some unique features in Asia [1] . To understand the pathophysiologic mechanism, we need experimental models. Animal models could be useful but may have limitations. In this issue, Hung et al. [2] described 'human ex vivo and in vitro disease models' to study food allergy. This issue also contains a pilot study on oral immunotherapy for peanut allergy from Singapore [3] . Readers will find an interesting study on carminic acid in cochineal dye (used as a food additive) induced anaphylaxis [4], and a rare case of anhidrotic ectodermal dysplasia presenting with pyrexia, atopic eczema, and food allergy [5] .
Now is an era of biological therapy as 'precision medicine.' In the field of allergy, anti-IgE (omalizumab), anti-interleukin (IL)-5 (mepolizumab, reslizumab, and benralizumab) and anti-IL4Rα(dupilumab) monoclonal antibodies are used in current practice, and others are under clinical trials [6] . Omalizumab is the first biological agent for allergic diseases (asthma, and chronic urticaria). Readers will find a very nice review article of 'omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children' in this issue [7] .
Exposure to daily chemicals may be associated with allergen sensitization and allergic diseases [8, 9] . Triclosan and paraben are chemicals used in personal care and medical products as microbicides and preservatives [10] . Mitsui-Iwama et al. [11] present the first
